What is the 13F Pro Quality Score for TELA?

13F Pro ranks TELA Bio, Inc. (TELA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TELA's current score at https://13fpro.ai/company/TELA (free sign-up required for the full ranking).

Where does 13F Pro source TELA data?

All TELA Bio, Inc. fundamentals and ownership data come directly from SEC EDGAR. TELA Bio, Inc. files with the SEC under CIK 1561921. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TELA in?

TELA Bio, Inc. (TELA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives TELA's revenue?

Per TELA Bio, Inc.'s latest 10-Q filed with the SEC on 2026-08-11, the biggest revenue drivers are: OviTex ($13.3M, +6% YoY); OviTex PRS ($5.5M, -26% YoY); Other ($0.5M, +39% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/TELA.

What are TELA's largest expenses?

TELA Bio, Inc.'s latest 10-Q reports these as the largest expense items: Sales and marketing ($16.4M, -2% YoY); Research and development ($2.7M, +24% YoY); General and administrative ($4.1M, -2% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is TELA research updated on 13F Pro?

TELA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TELA Bio, Inc.(TELA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1561921 TELA stock profile & AI dashboard →

13F Pro Quality Score

25.2/100

Rank #2,671 of 2,960 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

67.9/100

Profitability

11.0/100

Balance Sheet

2.4/100

Earnings Quality

25.9/100

Free Cash Flow

10.4/100

Institutional Flow

8.1/100

Revenue Scale

12.9/100

Dilution Risk

25.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TELA Scores 25/100

exact factor attribution · 2026-09-11

TELA's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+3.6 pts

68th pct

Earnings growth

-0.6 pts

39th pct

Shareholder dilution

-1.2 pts

26th pct

Institutional flow

-2.1 pts

8th pct

Earnings quality

-2.4 pts

26th pct

Capital efficiency

-4.8 pts

2th pct

Scale

-5.6 pts

13th pct

Profitability

-5.8 pts

11th pct

Free cash flow

-5.9 pts

10th pct

Latest change (2026-08-11): 25 → 21 · ↓ Revenue growth 77→53

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

TELA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for TELA Bio, Inc. (TELA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TELA at 25.2/100 on a 32-signal composite quality model, placing it at rank #2,671 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (2.4) and institutional flow (8.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TELA Bio, Inc. reports quarterly revenue of $19.3M, net income of $-11.3M, an operating margin of -48.1%. Top institutional holders of TELA by reported 13-F value include Essex Woodlands Management, Nantahala Capital Management, Stonepine Capital Management, based on the most recent SEC filings. TELA trades on the Nasdaq exchange and files with the SEC under CIK 1561921. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TELA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TELA Bio, Inc. directly from SEC EDGAR. TELA Bio, Inc.'s 13F Pro composite quality score has ranged between 21 and 32 since 2022, currently 25.2 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.

✦

Fun facts about TELA Bio, Inc.

Quirks, history, and lore behind TELA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the range of roughly $60–80 million — a true small-cap grinder — with a commercial focus on a single surgical category.
3
The History
Founded in the 2010s and built around technology licensed from academic research, it went public to fund the rollout of its first commercial product line.
4
The Secret
Its products are made from porcine (pig) tissue and a proprietary polymer matrix, designed to mimic how the body's own abdominal wall is structured.
5
The Lore
Its flagship product, OviTex, is a reinforced tissue matrix used in hernia repair — one of the most common surgical procedures performed worldwide.
6
The Giveaway
The name is literally a mashup of "tissue engineering" and "biologic" — a Pennsylvania med-tech shop stitching its way through the hernia repair market one OviTex implant at a time.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving TELA's Business? Latest 10-Q Breakdown

✓ 29/29 datapoints verified

AI-extracted from TELA Bio, Inc.'s 10-Q filed 2026-08-11 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

TELA Bio's Q2 revenue declined 4% YoY to $19.3M as OviTex PRS sales fell 23% in units, offset partially by 12% OviTex volume growth, while net loss widened 13% to $11.3M due to higher interest expense from new $60M debt facility.

Biggest Revenue Drivers

OviTex$13.3M+6% YoY

Volume increased 12% in units to 5,776 despite price mix headwinds from smaller sized units.

OviTex PRS$5.5M-26% YoY

Unit sales declined 23% to 1,050 units, primary driver of overall revenue decline.

Biggest Revenue Drivers

Total revenue: $19.3M-4% YoY

OviTex$13.3M+6% YoY

Volume increased 12% in units to 5,776 despite price mix headwinds from smaller sized units.

OviTex PRS$5.5M-26% YoY

Unit sales declined 23% to 1,050 units, primary driver of overall revenue decline.

Other$0.5M+39% YoY

Includes LIQUIFIX distribution and other product offerings.

Largest Expense Items

Sales and marketing$16.4M-2% YoY

Lower compensation from headcount reductions offset by higher meeting and training costs.

Research and development$2.7M+24% YoY

Higher compensation from additional headcount and increased study costs.

General and administrative$4.1M-2% YoY

Lower compensation from headcount reduction partially offset by higher professional fees.

Interest expense$2.1M+75% YoY

Increase due to larger borrowing base and higher interest rate under new Perceptive credit facility at 7.85% margin.

Margins: Gross margin improved to 72% from 70% YoY, primarily due to lower excess inventory charges as a percentage of revenue and a $0.6M tariff refund. However, operating losses persisted as revenue decline offset margin gains, with operating loss of $9.3M versus $9.1M in prior year.

Watch Items from the Filing

Going concern risk: Company has substantial doubt about ability to continue as going concern. Forecasts indicate probable noncompliance with minimum revenue covenant under Perceptive Credit Agreement within 12 months despite $30.4M cash; default could trigger acceleration of full $60M debt.
OviTex PRS revenue decline: Unit sales fell 23% YoY in Q2 to 1,050 units, representing primary revenue headwind; product lineup represents 28% of total revenue.
Tariff exposure: Company pays 12.5% U.S. tariff on products manufactured in New Zealand; Aroa agreement requires equal cost sharing, creating price and demand risk.
Interest expense surge: Interest expense increased 75% YoY to $2.1M in Q2 due to $60M Perceptive facility at variable rate; represents significant drag on path to profitability.
Cash burn accelerating: Operating cash burn of $20.6M for six months ended June 30, 2026 versus $17.6M in prior year period; cash declined from $50.8M to $30.4M in six months.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$19.3M

Net Income

Q2 2026

$-11.3M

Free Cash Flow

Q2 2026

$-9.4M

Operating Margin

Q2 2026

-48.1%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+15.8% YoY

$80.3MFY 2025

FY22 $41.4MFY23 $58.5MFY24 $69.3MFY25 $80.3M

Net Income

-2.6% YoY

$-38.8MFY 2025

FY22 $-44.3MFY23 $-46.7MFY24 $-37.8MFY25 $-38.8M

Operating Income

+1.1% YoY

$-33.8MFY 2025

FY22 $-39.0MFY23 $-44.1MFY24 $-34.1MFY25 $-33.8M

EPS (Diluted)

+37.6% YoY

$-0.83FY 2025

FY22 $-2.72FY23 $-2.04FY24 $-1.33FY25 $-0.83

Total Assets

-6.0% YoY

$81.4MFY 2025

FY22 $67.9MFY23 $78.0MFY24 $86.6MFY25 $81.4M

Total Debt

+35.3% YoY

$55.7MFY 2025

FY22 $39.9MFY23 $40.5MFY24 $41.1MFY25 $55.7M

Op. Cash Flow

+32.2% YoY

$-28.2MFY 2025

FY22 $-40.7MFY23 $-40.9MFY24 $-41.6MFY25 $-28.2M

Free Cash Flow

+32.7% YoY

$-28.7MFY 2025

FY22 $-41.6MFY23 $-41.5MFY24 $-42.6MFY25 $-28.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$80.3M +15.8%	$69.3M +18.6%	$58.5M +41.1%	$41.4M +40.6%	$29.5M +61.8%	$18.2M
Net Income	$-38.8M -2.6%	$-37.8M +18.9%	$-46.7M -5.3%	$-44.3M -33.1%	$-33.3M -15.6%	$-28.8M
Operating Income	$-33.8M +1.1%	$-34.1M +22.6%	$-44.1M -13.0%	$-39.0M -32.4%	$-29.5M -16.5%	$-25.3M
EPS (Diluted)	$-0.83 +37.6%	$-1.33 +34.8%	$-2.04 +25.0%	$-2.72 -18.3%	$-2.30 -3.1%	$-2.23
Total Assets	$81.4M -6.0%	$86.6M +10.9%	$78.0M +15.0%	$67.9M +8.5%	$62.5M -27.7%	$86.5M
Total Debt	$55.7M +35.3%	$41.1M +1.5%	$40.5M +1.5%	$39.9M +26.8%	$31.5M +2.2%	$30.8M
Operating Cash Flow	$-28.2M +32.2%	$-41.6M -1.8%	$-40.9M -0.3%	$-40.7M -33.9%	$-30.4M -24.4%	$-24.5M
Free Cash Flow	$-28.7M +32.7%	$-42.6M -2.7%	$-41.5M +0.4%	$-41.6M -34.0%	$-31.1M -26.1%	$-24.6M

Get alerted when TELA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TELA Bio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TELA

Essex Woodlands Management, Inc.
$5.8M7,714,709 sh
Nantahala Capital Management, LLC
$4.4M5,894,114 sh
Stonepine Capital Management, LLC
$2.0M2,662,427 sh
SILVERARC CAPITAL MANAGEMENT, LLC
$1.6M2,137,201 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.2M1,568,218 sh
DAFNA Capital Management LLC
$1.1M1,441,029 sh
PERKINS CAPITAL MANAGEMENT INC
$1.0M1,375,042 sh
Sio Capital Management, LLC
$477.2K636,300 sh
WealthTrust Axiom LLC
$343.3K457,734 sh
GEODE CAPITAL MANAGEMENT, LLC
$292.0K389,223 sh

Fund	Value	Shares
Essex Woodlands Management, Inc.	$5.8M	7,714,709
Nantahala Capital Management, LLC	$4.4M	5,894,114
Stonepine Capital Management, LLC	$2.0M	2,662,427
SILVERARC CAPITAL MANAGEMENT, LLC	$1.6M	2,137,201
VANGUARD CAPITAL MANAGEMENT LLC	$1.2M	1,568,218
DAFNA Capital Management LLC	$1.1M	1,441,029
PERKINS CAPITAL MANAGEMENT INC	$1.0M	1,375,042
Sio Capital Management, LLC	$477.2K	636,300
WealthTrust Axiom LLC	$343.3K	457,734
GEODE CAPITAL MANAGEMENT, LLC	$292.0K	389,223

Companies Similar to TELA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

VRCA

Verrica Pharmaceuticals Inc.

AI score

Similar quality profile · 2 shared holders

Stonepine Capital Management, LLC DAFNA Capital Management LLC

ADCT

ADC Therapeutics SA

AI score

Similar quality profile · 2 shared holders

Nantahala Capital Management, LLC DAFNA Capital Management LLC

LUNG

Pulmonx Corp

AI score

Similar quality profile · 2 shared holders

Stonepine Capital Management, LLC PERKINS CAPITAL MANAGEMENT INC

OVID

Ovid Therapeutics Inc.

AI score

Similar quality profile · 4 shared holders

SILVERARC CAPITAL MANAGEMENT, LLC Sio Capital Management, LLC Stonepine Capital Management, LLC

XGN

EXAGEN INC.

AI score

Similar quality profile · 1 shared holders

PERKINS CAPITAL MANAGEMENT INC

APYX

Apyx Medical Corp

AI score

Similar quality profile · 2 shared holders

Nantahala Capital Management, LLC PERKINS CAPITAL MANAGEMENT INC

KIDS

ORTHOPEDIATRICS CORP

AI score

Similar quality profile · 2 shared holders

Nantahala Capital Management, LLC DAFNA Capital Management LLC

STXS

Stereotaxis, Inc.

AI score

Similar quality profile · 1 shared holders

DAFNA Capital Management LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TELA on your watchlist

Track score changes the day TELA Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TELA a good stock to buy?

13F Pro's AI-powered analysis of TELA Bio, Inc. (TELA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TELA are available on the TELA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TELA is classified as a small company.

Which hedge funds own TELA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TELA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TELA Bio, Inc.'s investment landscape.